ReviewTherapeutics and clinical risk management2014
Epidemiology and risk factors for invasive candidiasis.
Review in Therapeutics and clinical risk management, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 270 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
270 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Global prevalence, mortality, and comorbidities of patients with diabetes mellitus and proven Candida auris emerging infection: a systematic review & meta-analysis.BMC infectious diseases · 2026Pooled it
- Risk of invasive candidiasis with prolonged duration of ICU stay: a systematic review and meta-analysis.BMJ open · 2020Pooled it
- Beyond Tuberculosis: Unlocking the Antifungal Potential of Novel Isoniazid Derivatives against Non-ACS omega · 2026Article
- From Oral Candidiasis to Candidemia: A Review of Superficial to Invasive Progression.MicrobiologyOpen · 2026Review
- Observational
- Shift in Candidemia Epidemiology and Emerging Fluconazole Resistance inJournal of fungi (Basel, Switzerland) · 2026Article
- Article
- Glycogen phosphorylase L confers metabolic flexibility in neutrophils to fight fungal infections in nutrient-deprived tissues.Cell host & microbe · 2026Article
- The novel second-generation triterpenoid SCY-247 maintainsAntimicrobial agents and chemotherapy · 2026Article
- Article
- Avian Candidiasis: A Comprehensive Review of Pathogenesis, Diagnosis, and Control.Veterinary sciences · 2026Review
- Diagnostic Biomarkers for Invasive Candidiasis: A Clinician-Oriented Review.Journal of fungi (Basel, Switzerland) · 2026Review
- Article
- Amyloid fibrils of the Als5p-derived peptide NHVirulence · 2025Article
- Advances in Fungal Infection Research: From Novel Diagnostics to Innovative Therapeutics.Journal of fungi (Basel, Switzerland) · 2025Article
- Biotherapeutic Potential of Probiotic YeastIndian journal of microbiology · 2025Article
- Invasive Candidiasis in Contexts of Armed Conflict, High Violence, and Forced Displacement in Latin America and the Caribbean (2005-2025).Journal of fungi (Basel, Switzerland) · 2025Review
- Pathogenicity Evaluation on Fluconazole-Resistant Candida auris Clade V in Murine Model.Mycopathologia · 2025Article
- Review
- Targeting Azole-ResistantVaccines · 2025Article
210 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The number of immunosuppressive patients has increased significantly in recent years. These patients are at risk for opportunistic infections, especially fungal infections. Candidiasis is one of the most frequent fungal infections determined in these immunosuppressive patients and its epidemiology has changed over the last two decades. Recently, new antifungal agents and new therapy strategies such as antifungal prophylaxis, secondary prophylaxis, and preemptive therapy have come into use. These changes resulted in the alteration of Candida species causing invasive infections. The incidence of Candida albicans was decreased in many countries, especially among patients with immunosuppressive disorders, while the incidence of species other than C. albicans was increased. In this review, incidence, risk factors, and species distribution of invasive candidiasis are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.